Pete Gough, NSF, presents a white paper on the implications of Brexit and what it means for the UK pharmaceutical industry
The only thing that is certain following the UK’s momentous decision to leave the European Union (EU), so called Brexit, is that the pharmaceutical industry, as all others, is facing at least two, and probably many more, years of unprecedented uncertainty.
One theoretical possibility is that the UK will seek to join Norway, Lichtenstein and Iceland in the European Economic Area (EEA).
If this were to happen, then in practical terms for medicinal products comparatively little would need to change. However, politically, it would appear to be very unlikely that the UK will seek to join the EEA.
If the UK does not elect to join the EEA, it will become a third country as far as the EU is concerned and this will lead to much more profound changes.
Interested in finding out more? Download the full white paper from NSF.